GNAS1 direct sequencing

GNAS1 mutation analysis was performed for codon 201 (exon 8) and codon 227 (exon 9) using oligonucleotide primers extended with an M13-forward or reverse sequence (see supplementary Table 1). Tumour tissue was isolated from formalin-fixed, paraffin-embedded material (FFPE) by microdissection to enrich for tumour cells and avoid 'contamination' of non-neoplastic cells, that is, lymphocytes, endothelial cells/pericytes or muscular tissue at the periphery of the tumour.
Genomic DNA was isolated from 10 consecutive 10-mm sections using a Chelex extraction method, as described earlier [15] . Polymerase chain reaction (PCR) was carried out to amplify the GNAS1 gene with the primers for exon 8 and exon 9, as previously reported [16] . PCR products were visualized and sequenced as previously described [17, 18] .
GNAS1 multiplex ligation-dependent probe amplification (MLPA)
To detect mutations that are missed by direct sequencing due to contamination with normal cells, we set up GNAS1 MLPA for the mutations already detected by direct sequencing. MLPA was performed using the following oligonucleotide probes attached to M13-tail, depicted in supplementary  Table 3 . For the R201C mutant, probes with additional stuffer sequence were added: forward: 5Ј-CAGAC-3Ј and reverse 5Ј-GATGTGCT-3Ј. MLPA was performed as previously described [19] . In short, adjacently annealing oligonucleotide probes were hybridized and ligated. After ligation, the common ends of the probes served as a template for PCR amplification using the primer pairs that are depicted in supplementary Table 1 ). All primer sequences and amplification protocols have been previously described [20] . PCR products were purified with the QIAquick PCR Purification Kit (Qiagen, Germantown, MD) 
KRAS mutation analysis
KRAS mutation analysis was performed on microdissected FFPE tumour tissue using two primer sets in a nested PCR which specifically amplifies a 114 bp fragment of KRAS exon 2, including codons 12 and 13 (supplementary
and sequenced with the fluorescent Big-Dyes Terminators Sequencing Kit (Applied Biosystems).
TP53 mutation analysis
TP53 hotspot mutation analysis was performed on microdissected FFPE tumour tissue using primer sets for exons 4a, 4b, 5c, 6, 7 and 8 in a nested PCR (supplementary Table 2 ). Samples were used in high-resolution melting curve analysis as previously described [46] . PCR products were purified with the QIAquick PCR Purification Kit (Qiagen) and sequenced with the fluorescent Big-Dyes Terminators Sequencing Kit (Applied Biosystems).
SDS-PAGE, in-gel tryptic digestion and mass spectrometry
Tumour lysates of intramuscular myxoma and grade I myxofibrosarcoma were prepared and depleted of albumin and IgG as previously described [11] . From 
qPCR for mRNA expression
Following microdissection, RNA isolation and purification, qPCR was performed for c-Fos, decorin, collagen I alpha 1, collagen VI alpha 1, collagen XII alpha 1 and collagen XIV alpha 1, as described previously [11, 22, 23] .
Primers (including those of the housekeeping genes) and controls are summarized in supplementary Table 1. A reference control panel, including a variety of neoplastic and non-neoplastic tissue was used as described
Fig. 1 Overlapping histology of intramuscular myxoma, cellular myxoma and grade I myxofibrosarcoma and their immunohistochemical expression for c-Fos, decorin, collagen I, collagen VI and CD44. (A) Low-power view of intramuscular myxoma showing a hypocellular and hypovascular tumour. Its cellular variant is both more cellular and more vascular (B) but lacks the cytonuclear atypia and characteristic curvilinear vascular pattern of grade I myxofibrosarcoma (C). Low-power view of intramuscular myxoma (D) showing moderate cytoplasmic and nuclear expression for c-Fos in the majority (Ͼ75%) of tumour cells. (E) Low-power view of intramuscular myxoma was completely negative for decorin, whereas grade I myxofibrosarcoma showed diffuse fibrillary staining for decorin in the ECM (F). Lack of collagen I expression in the ECM of intramuscular myxoma (G) and moderate staining for collagen VI in the ECM of grade I myxofibrosarcoma (H). A majority of tumour cells of grade I myxofibrosarcoma showed strong membranous staining for CD44 in the majority of tumour cells (I).
previously [24] . After qPCR, the products were purified using QIAquick Table 4 [11, 25] . For c-Fos and CD44, only nuclear and membranous staining were assessed, respectively, and scored as previously described [26] . For decorin, collagen I-A1 and collagen VI-A1, the ECM of whole sections were assessed. Scores of 0 (absent) and 1 (weak) were considered negative; scores of 2 (moderate) and 3 (strong) were considered positive.
PCR Purification Kit (Qiagen). For sequence confirmation of the products, we used the Big Dyes Terminators Sequencing Kit (Applied Biosystems).
Immunohistochemistry
Immunohistochemistry was performed for c-Fos, decorin, collagen I-A1, collagen VI-A1 and CD44. Sections (4-m-thick) were mounted on 3-aminopropylethoxysilane (Sigma, St. Louis, MO) and glutaraldehydecoated slides and dried overnight at 37ЊC. Immunohistochemistry was performed as previously described, using the antibodies, conditions and controls described in supplementary
Statistical analysis
Wilcoxon-Mann-Whitney test was used to calculate the differences for both the immunohistochemical and qPCR results. 
LC-MS
The top 30 proteins identified in a proteomic screen of tumour lysates of grade I myxofibrosarcoma and intramuscular myxoma are shown in Table 3 .
Even after depletion, albumin was still the most prominent protein, and also other 'classical' serum proteins were among the most significant hits. We found five collagens (VI-A1, 2 and 3, XII-A1, XIV-A1) and five proteoglycans (lumican, PRG4, prolargin, decorin and biglycan) among the top 30 proteins in MFS. Only the collagen VI isoforms and lumican were identified in IM. Besides collagen VI isoforms and lumican, the other four collagens and four proteoglycans were not shown to be present in IM using mass spectrometry.
qPCR for mRNA expression
Results of relative mRNA expression are shown in Table 4 and box-plots in Fig. 2 . Fig. 1 [31] . This was sustained by previous data that p53 immunohistochemical staining was predominantly found in myxofibrosarcoma of grade II and III [10] . Cytogenetic data on intramuscular myxoma are sparse in the literature, with only two isolated cases described showing normal karyotypes [4, 32] . The present study confirms in a larger series that intramuscular myxoma has a normal karyotype. Cytogenetics might therefore be helpful in the differential diagnosis but are not always easily available in routine laboratories. Okamoto et al. showed GNAS1-activating mutations in a small series of intramuscular myxoma [6] . We showed that GNAS1 codon 201 mutations were present in 50% of intramuscular myxoma and not in grade I myxofibrosarcoma. All mutations were heterozygous. Direct sequencing of codon 201 GNAS1 mutations is therefore a highly specific, not very sensitive but easy to perform method to distinguish intramuscular myxoma from grade I myxofibrosarcoma. Interestingly, here we report for the first time the R201S mutation in intramuscular myxoma. We could not detect any mutation in codon 227 (exon 9) of the GNAS1 gene, previously detected in fibrous dysplasia [33] [7, [33] [34] [35] . This leads to increased transcription of the c-Fos protein, which is involved in growth and the inhibition of apoptosis [36] . We showed both RNA and protein over-expression for c-Fos in each of the tumour 
qPCR showed that c-Fos RNA was overexpressed in all tumours compared with control tissue, but not significantly differently expressed between intramuscular myxoma and grade I myxofibrosarcoma. No significant differences were seen between typical intramuscular myxoma and cellular myxoma. Grade I myxofibrosarcoma showed significant expression of decorin mRNA, whereas decorin mRNA was barely detectable in intramuscular myxoma. Grade I myxofibrosarcoma clearly showed significant over-expression of mRNA expression for collagens I-A1, VI-A1 and XIV-A1 compared with intramuscular myxoma (including cellular myxoma).
Immunohistochemistry
The majority of intramuscular myxomas and grade I myxofibrosarcomas showed diffuse cytoplasmic and nuclear staining for c-Fos (Table 5). Both cytoplasmic and nuclear staining for c-Fos have been obtained in FFPE materials from other tumours [27]. However, the biological role of cytoplasmic c-Fos expression is not fully understood. And because c-Fos is a transcription factor that is active in the nucleus, we assessed only nuclear staining in scoring. Intramuscular myxoma and grade I myxofibrosarcoma did not show significantly different c-Fos expression (P ϭ 0.648; Table 5). Decorin, collagen I-A1 and collagen VI-A1 were only present in the ECM. Strong positive staining for decorin was detected in all grade I myxofibrosarcomas but not in intramuscular myxoma, including its cellular variant (P ϭ 0.0000). Collagen I-A1 expression was found to be equally present in the ECM of grade I myxofibrosarcoma and intramuscular myxoma (P ϭ 1.000). Collagen VI-A1 expression was present in 40% of the ECM of intramuscular myxoma and all grade I myxofibrosarcoma (P ϭ 0.004). Illustrations of collagen I-A1 and VI-A1 protein expression are shown in
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